oral semaglutide novo nordisk novonordisk has received European Commission approval for Wegovy® pill, the European Union's first GLP-1 receptor agonist for chronic weight management. The once-daily oral is approved for adults with obesity or Here's Novo Nordisk's First Oral

Ask about hormonal context: discuss menopausal status, contraceptive use, and pregnancy plans before initiating agents with systemic metabolic effects

This fund serves a crucial role in compensating individuals who, in rare occurrences, experience detrimental side effects, such as SIRVA or severe allergic reactions, due to their meningitis vaccination or any other vaccine under VICP purview

Medical Conditions: Inform the healthcare provider of any pre-existing conditions, especially issues related to heart, kidney, or liver health

The safety and efficacy of tirzepatide in pediatric populations have not been established, as there have been no well-controlled clinical trials evaluating its effects in children